

November 30, 2007

Sanofi-aventis and Astellas to restructure their joint venture activities of Fujisawa sanofi-aventis K.K. in Japan

Sanofi-aventis and Astellas Pharma Inc. (hereinafter: "Astellas", Headquarters: Tokyo, Japan, President and CEO: Masafumi Nogimori) announced today that they have agreed to restructure their joint venture activities in Japan (Fujisawa sanofi-aventis K.K. ,hereinafter: "FSA"). This operation, that will simplify the operational management, will be made in several steps and the process is expected to be completed substantially on December 31, 2007.

Established in 1982, FSA is a joint venture company 51% owned by sanofi-aventis and 49% by Astellas. FSA owns the rights to manufacture and sell certain products originating from sanofi-aventis such as Myslee[®] (zolpidem), Dogmatyl[®] (sulpiride), Primperan[®] (metoclopramide) and Gramalil[®] (tiapride) .

In the restructuring, sanofi-aventis K.K., the Japanese subsidiary of sanofi-aventis, shall obtain certain rights to Myslee. Myslee[®], the leading treatment of insomnia, will continue to be co-promoted by sanofi-aventis K.K. and Astellas and distributed by Astellas. The other products, namely Primperan[®], Dogmatyl[®] and Gramalil[®] will solely be marketed and distributed by Astellas.

#####

Contacts for inquiries or additional information
sanofi-aventis K.K. Communications External Communications Tel: +81-3-6301-4148 http://www.sanofi-aventis.co.jp
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 http://www.astellas.com